Out-of-hospital cardiac arrest is one of the leading causes of death in developed countries and is a real challenge because survival rates are still very low, often less than 10%. Cardiac arrest registries have proven to be an essential tool in improving the survival of cardiac arrest victims, as they allow us to measure the phenomenon and consequently improve treatment. Ten years ago, we have started collecting data in the province of Pavia, then extended to the provinces of Brescia, Como, Cremona, Lodi, Mantua and Varese, with the aim of achieving regional coverage.
View Article and Find Full Text PDFMany studies aimed at understanding the electrophysiological mechanisms of ventricular fibrillation (VF) and defibrillation. Although many theories have been proposed about VF, we are still far from fully understanding it. Research has revealed significant insights provided by VF waveform, particularly through its amplitude of spectral area (AMSA).
View Article and Find Full Text PDFIntroduction: Immunosuppressive treatment is effective in most Myasthenia gravis patients, but 10-15% of patients areconsidered refractory due to inadequate response or intolerance to therapy. Eculizumab, a humanized monoclonalantibody directed against C5 complement protein, was approved in Italy to treat Ab-AchR generalized refractoryMG (rMG) in October 2022.
Aim: We aim to describe a real-world Italian experience in a population of refractory myasthenia gravis patients with oneyear follow up.